Drug Trial News

RSS

Review of probiotics in the treatment of Irritable Bowel Syndrome

A review by researchers at Northwestern University (Chicago, IL.) and University of Michigan (Ann Arbor, MI) of the utility of probiotics in the treatment of Irritable Bowel Syndrome (IBS) found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty.

23 Mar 2009

NEJM Letters respond to recent studies on malaria vaccines, treatments

The New England Journal of Medicine in its March 19 issue featured a letter to the editor written in response to a study published in its Dec. 11 issue reporting the results of the RTS,S/AS01E malaria vaccine trial.

23 Mar 2009

Cathepsin B increases apoptosis in fulminant hepatic failure

The traditional view is that hepatocyte necrosis is the main feature of fulminant hepatic failure, but increasing evidence implicates a dominant role for hepatocyte apoptosis in this pathogenesis.

22 Mar 2009

SemBioSys Genetics announces clinical results with plant-produced insulin

SemBioSys Genetics Inc., specializing in the manufacture of high-value proteins and oils in plant seeds, today announced preliminary results of its first "in-man" clinical study of SBS-1000, a recombinant human insulin manufactured using its proprietary platform.

20 Mar 2009

Potential colon cancer being tested

Researchers at the University of Pittsburgh School of Medicine have begun testing a vaccine that might be able to prevent colon cancer in people at high risk for developing the disease.

20 Mar 2009

Drug pactimibe does not appear to reduce progression of atherosclerosis

Compared to placebo, the drug pactimibe did not effect certain measures of atherosclerosis for patients with familial hypercholesterolemia (high cholesterol levels), but these patients did have an increased incidence of cardiovascular events such as heart attack and stroke, according to a study in the March 18 issue of JAMA.

17 Mar 2009

Cephalon announces positive results from study of NUVIGIL in bipolar depression

Cephalon, Inc. has announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder.

17 Mar 2009

Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate

Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

17 Mar 2009

Budesonide nasal wash shows promise for chronic rhinosinusitis

A nasal wash containing the corticosteroid budesonide appears to reduce symptoms of chronic rhinosinusitis without suppressing the function of the adrenal glands, a known complication of this type of drug that would indicate absorption throughout the whole body, according to a report in the March issue of Archives of Otolaryngology-Head & Neck Surgery.

16 Mar 2009

Trial of new combination treatment targeting hormone receptor-positive locally advanced breast cancer

Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial, which aims to evaluate a new treatment for breast cancer in combination with one that is already approved for other types of cancers.

16 Mar 2009

Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions

Helix BioPharma Corp. announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

16 Mar 2009

Healthpoint intiates phase II clinical trial to evaluate effectiveness of HP802-247 in venous leg ulcers

Healthpoint announced that it has initiated a Phase II clinical trial investigating the efficacy of HP802-247 in venous leg ulcers.

16 Mar 2009

Nobilon's intranasal influenza vaccine begins phase I clinical development

Nobilon, the human vaccine business unit of Schering-Plough Corporation has announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

15 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

BioCis Pharma starts trial of novel topical drug for dermatology

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure emulsion cream, the company's novel topical drug for dermatology.

12 Mar 2009

Rituximab may be effective in treating membranous nephropathy

Current treatments for membranous nephropathy are limited to steroids, calcineurin inhibitors, and chemotherapeutic agents, all of which have significant side effects.

11 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Rituximab useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

11 Mar 2009

Long-term effects of two common drugs for early Parkinson's similar

A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

10 Mar 2009